Recent Finacing
Recent Raise
Prime Medicine develops prime‑editing therapies using a Cas nickase–reverse transcriptase and pegRNAs to edit DNA without double‑strand breaks, advancing preclinical programs for CF, liver, eye, HSC, and neuromuscular indications.
